A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.
James R. Berenson(Oncotherapeutics (United States)), Sal Bevivino(Oncotherapeutics (United States)), David S. Siegel(Hackensack Meridian Health), Syed Jilani(Eye Care Associates), Edward A. Stadtmauer(University of Pennsylvania), Marek J. Bozdech, Joseph Volk(Palo Verde Hospital), Jose Lutzky, Ravi Patel(Comprehensive Blood & Cancer Center), J. Talisman Pomeroy, Delina Ferreti(Institute for Myeloma & Bone Cancer Research), Tiberio Lindgren, Alberto Bessudo(California Cancer Associates for Research and Excellence), Robert A. Moss(Valley Regional Hospital), Ronald G. Steis, Howard Yeh(Hospital de Santa Maria), Ralph V. Boccia, Marshall S. Flam
Cited by 5
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540